Du är här

2016-01-18

Santhera Pharmaceuticals Holding AG: Santhera Signs Distribution and Supply Agreement for Raxone® with Ewopharma Covering Eastern Europe and The Baltics

Santhera Pharmaceuticals Holding AG / Santhera Signs Distribution and Supply
Agreement for Raxone® with EwopharmaCovering Eastern Europe and The Baltics .
Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is
solely responsible for the content of this announcement.
Santhera Pharmaceuticals (SIX: SANN) announces that it has signed an agreement
with Ewopharma to launch Raxone®for the treatment of Leber's hereditary optic
neuropathy (LHON) in a number of Eastern European countries (Bulgaria,
Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia) and
the Baltics (Estonia, Latvia and Lithuania). LHON is a rare, heritable,
mitochondrial disease that leads to rapid, profound and usually permanent
blindness in otherwise healthy patients. Raxone is the first treatment option
for LHON and the first approved therapy for a mitochondrial disease.

"The agreement with Ewopharma represents an important achievement for Santhera
and underscores our commitment to making Raxone available to patients across
all EU member states," saidGiovanni Stropoli
, Santhera's Chief Commercial Officer for Europe. "We are confident that
Ewopharma's expertise in the field of rare diseases, coupled with their
understanding of the region, will greatly benefit patients with this
devastating disease."

"As an organization historically present in Eastern European and Baltic
countries with a specific focus on niche indications and diseases with high
unmet medical need, we are very excited to have an opportunity to team up
with Santhera to offer for the first time a treatment to patients with LHON,"
saidAlain Staub
, CEO and Chairman of the Board of Ewopharma. "We will make every effort to
introduce Raxone as quickly as possible in these countries."

About Leber's Hereditary Optic Neuropathy and the Therapeutic Use of Raxone

LHON is a heritable genetic disease causing blindness. The disease presents
predominantly in young, otherwise healthy adult males as rapid, painless loss
of central vision, usually leading to permanent bilateral blindness within a
few months of the onset of symptoms. About 95% of patients harbor one of
three pathogenic mutations of the mitochondrial DNA, which cause a defect in
the complex I subunit of the mitochondrial respiratory chain. This defect
leads to decreased cellular energy (ATP) production, increased reactive
oxygen species (ROS) production and retinal ganglion cell dysfunction, which
cause progressive loss of visual acuity and blindness. Raxone (idebenone), a
synthetic short-chain benzoquinone and a cofactor for the enzyme
NAD(P)H:quinone oxidoreductase (NQO1), circumvents the complex I defect,
reduces and scavenges ROS, restores cellular energy levels in retinal
ganglion cells and promotes recovery of visual acuity.

Raxone is an oral medication, authorized at a daily dose of 900 mg (given as 2
tablets three times a day with food), for the treatment of visual impairment
in adolescent and adult patients with LHON. Treatment should be initiated and
supervised by a physician with experience in LHON. Efficacy data come from
Santhera's randomized, placebo-controlled RHODOS trial and from the open
label Expanded Access Program, which together have demonstrated that vision
loss can be mitigated or reversed in patients treated with Raxone.

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical
company focused on the development and commercialization of innovative
pharmaceutical products for the treatment of orphan mitochondrial and
neuromuscular diseases. Santhera's lead product Raxone®is authorized in the
European Union for the treatment of Leber's hereditary optic neuropathy
(LHON). Santhera develops Raxone®in two additional indications, Duchenne
muscular dystrophy (DMD) and primary progressive multiple sclerosis (ppMS),
and omigapil for congenital muscular dystrophy (CMD), all areas of high unmet
medical need. For further information, please visit the Company's
websitewww.santhera.com.

About Ewopharma

Ewopharma AG, headquartered in Schaffhausen (Switzerland), is a pharmaceutical
marketing company with over 270 employees and focused on the markets of
Central Eastern Europe, where it has 15 local offices. With more than 50
years presence in the region, Ewopharma has gained extensive knowledge of
these countries, which has enabled Ewopharma to achieve a privileged position
in the area. Ewopharma activities cover all facets of the registration and
marketing of ethical and over the counter pharmaceuticals. The company offers
its services to partner companies either as a package or tailored to their
specific needs. Ewopharma is also a member of the RX-Alliance, a professional
cooperation network of successful pharmaceutical companies active in selected
European markets. Further information is available atwww.ewopharma.com.

Raxone®and Catena®are trademarks of Santhera Pharmaceuticals.

----------------------------------------------------------------------------------------------
| For further information, contact: |
| Thomas Meier, PhD, Chief Executive Officer Christoph Rentsch, Chief Financial Officer |
| Phone +41 61 906 89 64 Phone +41 61 906 89 65 |
| thomas.meier@santhera.com christoph.rentsch@santhera.com |
| |
| US investor contact: US Public Relations contact: |
| Hans Vitzthum, LifeSci Advisors, LLC Deanne Eagle, Planet Communications |
| Phone +1 212 915 2568 Phone +1 917 837 5866 |
| hans@lifesciadvisors.com deanne@planetcommunications.nyc |
| |
| Ewopharma contacts |
| Martin Hongler, VP Operation&Partner Relations Reto Schaberl, Head Business Development |
| Phone +41 52 633 09 99 Phone +41 52 633 09 91 |
| m.hongler@ewopharma.com reto.schaberl@ewopharma.com |
----------------------------------------------------------------------------------------------
Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of the Company to be
materially different from those expressed or implied by such statements.
Readers should therefore not place undue reliance on these statements,
particularly not in connection with any contract or investment decision. The
Company disclaims any obligation to update these forward-looking statements.

# # #

News Release Ewopharma
http://hugin.info/137261/R/1979280/725052.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Globenewswire

HUG#1979280

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.